DexCom, Inc. reported significant financial growth in its latest quarterly results, with revenues reaching $1.21 billion for the three months ended September 30, 2025, a 22% increase from $994.2 million in the same period last year. For the nine months ending September 30, 2025, total revenue was $3.40 billion, up 17% from $2.92 billion in the prior year. The company also saw a substantial rise in net income, which surged to $283.8 million for the third quarter, compared to $134.6 million in the previous year, marking an increase of 111%. For the nine-month period, net income was $569 million, a 15% increase from $424.5 million in 2024.
The growth in revenue was primarily driven by increased sales volume of DexCom's disposable sensors, attributed to the addition of approximately 500,000 to 600,000 net customers in 2024. However, the company faced pricing pressures due to rebate eligibility and changes in channel mix. Disposable sensor revenue accounted for about 97% of total revenue in the third quarter of 2025, compared to 96% in the same quarter of 2024. The gross profit for the third quarter was $731.4 million, reflecting a gross margin of 60.5%, up from 59.7% in the prior year.
In terms of operational developments, DexCom has continued to expand its product offerings, launching the Dexcom G7 in 2023 and the Stelo biosensor in August 2024. The company has also received FDA clearance for the Dexcom G7 15 Day CGM System for adults with diabetes. As of September 30, 2025, DexCom reported cash, cash equivalents, and short-term marketable securities totaling $3.32 billion, a significant increase from $2.58 billion at the end of 2024. This strong liquidity position supports ongoing investments in research and development, which totaled $157.5 million in the third quarter, up from $135.4 million in the same period last year.
DexCom's workforce has also expanded, contributing to increased selling, general, and administrative expenses, which rose to $331.4 million in the third quarter from $306.4 million a year earlier. The company continues to focus on strategic partnerships and product development to enhance its market position. Looking ahead, DexCom anticipates continued growth driven by its expanding customer base and product innovations, while also managing the challenges posed by market conditions and pricing dynamics. The company remains committed to investing in its core business and exploring new opportunities in metabolic health.
About DEXCOM INC
DexCom, Inc. designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes management. Its core products include the Dexcom G6, G7, and Dexcom ONE systems, providing real-time glucose data to patients, caregivers, and healthcare providers. The company focuses on innovation, integration with insulin delivery devices, and expanding access through partnerships, aiming to improve health outcomes and reduce diabetes-related complications worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.